BB TME
Alternative Names: BB-TMELatest Information Update: 09 Jun 2023
At a glance
- Originator BroadenBio
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 30 May 2023 Preclinical trials in Solid tumours in China (unspecified route) prior to May 2023
- 30 May 2023 Broaden bio plans a phase I trial for Solid tumours in USA in October 2023 (BroadenBio pipeline, May 2023)
- 30 May 2023 Broaden bio plans a phase I trial for Solid tumours in China in August 2023 (BroadenBio pipeline, May 2023)